News & Updates
Filter by Specialty:
Personalized faricimab dosing shows durable efficacy in nAMD
A treat-and-extend personalized treatment with faricimab based on disease activity results in sustained gains in vision or anatomic outcomes through 2 years in patients with neovascular age-related macular degeneration (nAMD), reports a study. Moreover, nearly four in five (80 percent) patients have achieved extended dosing intervals of 12 weeks or more.
Personalized faricimab dosing shows durable efficacy in nAMD
30 Jul 2024
RUBY update: Dostarlimab strengthens spot in the endometrial cancer treatment arena
The addition of dostarlimab to a carboplatin-paclitaxel (CP) chemotherapy regimen confers an overall survival (OS) benefit in women with primary advanced or recurrent endometrial cancer (EC), according to the second interim analysis of the ENGOT-EN6/GOG-3031/RUBY trial part 1.
RUBY update: Dostarlimab strengthens spot in the endometrial cancer treatment arena
30 Jul 2024
Does race/ethnicity affect the safety, efficacy of semaglutide?
A post hoc analysis of the Semaglutide Treatment Effect in People with Obesity (STEP) clinical trials has shown that the treatment effect and safety profile of semaglutide 2.4 mg, compared with placebo, are consistent across racial and ethnic subgroups.
Does race/ethnicity affect the safety, efficacy of semaglutide?
29 Jul 2024
Vibegron relieves OAB symptoms in men treated for BPH
Treatment with vibegron significantly improves overactive bladder (OAB) symptoms in men who are being treated for benign prostatic hyperplasia (BPH), including daily micturitions and urgency episodes, results from the phase III COURAGE trial have shown. It is well tolerated and has an acceptable safety profile, with adverse event (AE) rates similar to placebo.